1. Home
  2. XNCR vs DOMO Comparison

XNCR vs DOMO Comparison

Compare XNCR & DOMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XNCR
  • DOMO
  • Stock Information
  • Founded
  • XNCR 1997
  • DOMO 2010
  • Country
  • XNCR United States
  • DOMO United States
  • Employees
  • XNCR N/A
  • DOMO N/A
  • Industry
  • XNCR Biotechnology: Pharmaceutical Preparations
  • DOMO Computer Software: Prepackaged Software
  • Sector
  • XNCR Health Care
  • DOMO Technology
  • Exchange
  • XNCR Nasdaq
  • DOMO Nasdaq
  • Market Cap
  • XNCR 565.1M
  • DOMO 562.5M
  • IPO Year
  • XNCR 2013
  • DOMO 2018
  • Fundamental
  • Price
  • XNCR $8.73
  • DOMO $16.41
  • Analyst Decision
  • XNCR Buy
  • DOMO Buy
  • Analyst Count
  • XNCR 7
  • DOMO 7
  • Target Price
  • XNCR $27.50
  • DOMO $13.14
  • AVG Volume (30 Days)
  • XNCR 540.9K
  • DOMO 609.0K
  • Earning Date
  • XNCR 08-08-2025
  • DOMO 08-28-2025
  • Dividend Yield
  • XNCR N/A
  • DOMO N/A
  • EPS Growth
  • XNCR N/A
  • DOMO N/A
  • EPS
  • XNCR N/A
  • DOMO N/A
  • Revenue
  • XNCR $127,228,000.00
  • DOMO $317,052,000.00
  • Revenue This Year
  • XNCR N/A
  • DOMO $1.69
  • Revenue Next Year
  • XNCR $28.84
  • DOMO $2.45
  • P/E Ratio
  • XNCR N/A
  • DOMO N/A
  • Revenue Growth
  • XNCR N/A
  • DOMO N/A
  • 52 Week Low
  • XNCR $7.16
  • DOMO $6.01
  • 52 Week High
  • XNCR $27.24
  • DOMO $16.81
  • Technical
  • Relative Strength Index (RSI)
  • XNCR 47.62
  • DOMO 67.86
  • Support Level
  • XNCR $9.00
  • DOMO $15.60
  • Resistance Level
  • XNCR $9.45
  • DOMO $16.31
  • Average True Range (ATR)
  • XNCR 0.45
  • DOMO 0.72
  • MACD
  • XNCR -0.01
  • DOMO 0.05
  • Stochastic Oscillator
  • XNCR 21.76
  • DOMO 88.70

About XNCR Xencor Inc.

Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.

About DOMO Domo Inc. Class B

Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.

Share on Social Networks: